BTIG Reiterates Buy Rating on Vericel Corporation (VCEL)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to BTIG Reiterates Buy Rating on Vericel Corporation (VCEL)
August 26, 2024 12:30 PM EDT
TD Cowen analyst Joshua Jennings raised the price target on Vericel Corporation (NASDAQ: VCEL) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "VCEL announced that the FDA approved its supplemental BLA filing for MACI Arthro. Management had been guiding to a 3Q approval, so we are encouraged to see an FDA decision within the expected timeline. This approval represents an expansion of the current MACI offering to include... More
August 26, 2024 7:48 AM EDT
Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI ArthroTM provides a less invasive technique compared to the current approach, allowing surgeons to evaluate and... More
